Remove

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Under the Paperwork Reduction Act of 1995, no persons are required to re

Application Number		10560352		
Filing Date		2005-02-12		
First Named Inventor	David	David Bryant Batt		
Art Unit		10560352 - GAU: 1624		
Examiner Name				
Attorney Docket Number		ON-4-33227A		

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	Issue Date Name of Patentee or Application of cited Document		entee or Applicant ument	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
/DR/	1	6180631		2001-01-30		KUTSCHER BERNHARD ET AL.				
If you wisl	n to ac	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	of sited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wisl	n to ac	ldd additional U.S. Publi	shed Ap			information ENT DOCUM		d butto	nAdd Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T5
/DR/	1	WO0222597				2002-03-21	NOVARTIS ERFIN VERWALT GMBH	ID		
/DR/	2	WO02093164				2002-11-21	AXXIMA PHARMACEUTICA AG	ALS		
/DR/	3	WO03062220				2003-07-31	NOVARTIS PHAR GMBH	MA		
		(5 1 5 1					1	0 14 7 10		1

U.S.PATENTS

/Deepak Rao/ 03/17/2009

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10560352			
Filing Date		2005-02-12			
First Named Inventor	David	David Bryant Batt			
Art Unit		10560352 - GAU: 1624			
Examiner Name					
Attorney Docket Number		ON-4-33227A			

/DR/	4	WO03066613	2003-08-14	NOVARTIS PHARMA GMBH			
/DR/	5	WO03070173	2003-08-28	GUTKE HANS-JURGEN			
/DR/	6	WO03022833	2003-03-20	NAYLOR ANTOINETTE			
If you wis	h to a	dd additional Foreign Patent Docu	nent citation information p	lease click the Add button	Add		
		NON-P	ATENT LITERATURE DO	CUMENTS	Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					
/DR/	1	ZIMMERMAN, J ET AL., "Phenylamino-pyrimidine (PAP) derivatives: a new class", Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 6, no. 11, June 4, 1996, pp. 1221-1226					
/DR/	2	TANIS, KEITH Q. ET AL., "Two distinct phosphorylation pathways have additive", Molecular and Cellular Biology, vol. 23, no. 11, pp. 3884-3896, June 2003					
/DR/	3	RACHID, ZAKARIA ET AL., "Synthesis of pyrimidinopyridine-triazene conjugates", Bioorganic & Medicnal Chemistry Letters, Vol. 13, No. 19., pp. 3297-3300, 2003.					
If you wis	h to a	dd additional non-patent literature	document citation informat	tion please click the Add b	utton Add		
			EXAMINER SIGNATUR	RE .			
Examiner	Signa	ature /Deepak Rao/		Date Considered	03/17/2009		
		nitial if reference considered, wheth conformance and not considered.					

1 See Kind Codes of USPTO Patent Documents at https://www.USPTO.GOV or MPPP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 for Japanese patent documents, the indication of the year of the reign of the Emproor must precede. 3 happicant is to place a check mark here if 4 kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 3 hopicant is to place a check mark here if well and the proper must be preceded by the proper patent in the place and the proper must be preceded by the p

English language translation is attached.